Research of potencial impact of Psilocybin and ketamine in treatment of depression (SPNP20230712)

Basic information

Investigator: MUDr. Tomáš Páleníček, PhD.
Main recipient: National Institute of Mental Health (NIMH)
Research period: 1/4/2022 – 31/12/2025
Total budget: 8,000,000 CZK
Supported by: Foundation contribution

Annotation

The foundation contribution will enable coverage of personnel costs related to the implementation of research associated with the above-mentioned studies. Specifically, it will be used to cover personal expenses for: a Clinical Trial Manager, psychologists, therapists, physicians, a study nurse, senior and junior data analysts, a scientific assistant, a head of instrumentation and medical technology, and researchers conducting data measurement and analysis within the study. It will also cover fees under agreements for work performance for therapists and physicians.
The contribution will help stabilize the clinical trial team investigating the potential of psychedelics, ensure a fast data analysis process, and support the publication of completed results, which will in turn foster further local and global research. Last but not least, it will partially relieve study leaders, allowing space for the preparation of new projects, public and professional outreach, and strategic research planning.
Grant and institutional funds are insufficient to cover the team’s personnel expenses; they only cover the bare minimum of necessary items and fall far short of international standards or financial conditions in the private healthcare sector. This has led to a loss of researchers.